
|Videos|September 3, 2021
Bleeding risk in patients using Botox treatments and blood thinners
Author(s)Urology Times staff
“The notable feature was that the bleeding risk is very small. In our particular group, it was less than 1%,” says Jai Seth, MD.
Advertisement
In this video, Jai Seth, MD, discusses the findings of the Neurourology and Urodynamics study, “Intravesical onabotulinumtoxinA injections in patients on antiplatelet and anticoagulation therapy.” Seth is a consultant urological surgeon at St. George’s University hospital, London, UK.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
Pearls & Perspectives: Modern Semen Testing and Male Fertility Care, with Thomas Masterson, MD
4
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
5






